Recurrence of Drug-Induced Lupus Secondary to Vedolizumab Use in a Patient With Crohn's Disease.

Crohn's disease IBD drug-induced lupus infliximab vedolizumab

Journal

ACG case reports journal
ISSN: 2326-3253
Titre abrégé: ACG Case Rep J
Pays: United States
ID NLM: 101638398

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 06 05 2023
accepted: 22 12 2023
medline: 26 1 2024
pubmed: 26 1 2024
entrez: 26 1 2024
Statut: epublish

Résumé

Drug-induced lupus is an autoimmune phenomenon characterized by the development of systemic lupus erythematosus-like clinical features after drug exposure. The entity is a clinical diagnosis. Evaluation consists of recognizing systemic lupus erythematosus-like features, identifying an appropriate causative agent, observing elevations of characteristic autoantibodies, and obtaining positive response with drug discontinuation. Vedolizumab is an anti-α

Identifiants

pubmed: 38274296
doi: 10.14309/crj.0000000000001270
pii: ACGCR-23-0395
pmc: PMC10810571
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e01270

Informations de copyright

© 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.

Auteurs

Vanessa I Rodriguez (VI)

Department of Internal Medicine, University of South Florida, Tampa, FL.

Akshay Mathavan (A)

Department of Internal Medicine, University of Florida, Gainesville, FL.

Akash Mathavan (A)

Department of Internal Medicine, University of Florida, Gainesville, FL.

Diana N Rodriguez (DN)

Department of Internal Medicine, University of Florida, Gainesville, FL.

Catalina Sanchez Alvarez (CS)

Division of Rheumatology and Immunology, University of Florida, Gainesville, FL.

Angela Pham (A)

Division of Gastroenterology, Hepatology and Nutrition, University of Florida, Gainesville, FL.

Classifications MeSH